Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary’s drug registration application for Luvometinib Tablets, aimed at treating a type of neurofibroma in children, has been accepted by the National Medical Products Administration and placed on the List of Priority Review. The drug represents an innovative treatment for advanced solid tumors and other related conditions, with the company having invested RMB 499.15 million into its development thus far.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
